Semaglutide reduces heavy drinking in randomized trials, and the effect is modest. The largest trial, in The Lancet, cut heavy-drinking days by 13.7 percentage points more than placebo in patients with obesity. There is no approved indication for alcohol use disorder. Separately, in January 2026 FDA found no increased suicidality risk across 91 trials and asked for that warning to be removed from the labels.
Key points
- In The Lancet (2026), 108 patients with alcohol use disorder and obesity: heavy-drinking days fell 13.7 percentage points more than with placebo [2].
- In the first trial (48 patients, 9 weeks), lab alcohol intake and drinks per drinking day fell, but not drinking days [1].
- In Sweden, semaglutide was associated with fewer alcohol-related hospitalizations (aHR 0.64) [4].
- The FDA analyzed 91 trials with 107,910 patients, found no increased suicidality risk and asked for the warning to be removed [6].
US status (October 2026): Semaglutide is FDA-approved as Ozempic, Rybelsus and Wegovy, with no approved indication for alcohol use disorder. See the semaglutide status page.
The anecdote came first, then the cohorts
GLP-1 agonists act on reward circuits, and for years clinicians described patients who drank less. Cohorts suggested it. In one using electronic health records of 83,825 patients with obesity, semaglutide, vs other anti-obesity medications, was associated with a 50 to 56% lower risk of incident and recurrent alcohol use disorder over 12 months [5]. In Sweden, with 227,866 people with alcohol use disorder and a within-individual design, it was associated with fewer alcohol hospitalizations: aHR 0.64 for semaglutide and 0.72 for liraglutide, vs 0.98 for approved alcohol-use-disorder drugs [4].
Three trials now test it
| Trial | Design | Result |
|---|---|---|
| JAMA Psychiatry 2025 [1] | 48 adults, 9 weeks | Less alcohol consumed in the lab session, fewer drinks per drinking day, less craving. No change in drinks per day or drinking days |
| The Lancet 2026 [2] | 108 patients with obesity, 26 weeks, with CBT | Heavy-drinking days fell by 41.1 vs 26.4 percentage points. Difference 13.7 points (P = 0.0015) |
| Am J Psychiatry 2026 [3] | 50 patients, oral semaglutide | No effect on lab craving or drinks per day. Heavy-drinking days and drinks per drinking day fell |
- 13.7: percentage-point reduction in heavy-drinking days vs placebo (Lancet 2026) [2]
- aHR 0.64: alcohol hospitalization on semaglutide (Sweden) [4]
- 107,910: patients in the FDA suicidality analysis [6]
The honest reading: the signal is now replicated in trials, but the effects are modest and concentrated in heavy drinking [1][2][3]. There is no approved indication for alcohol use disorder. If a patient on a GLP-1 for weight reports drinking less, that fits the data. It is not a reason to prescribe for alcohol use alone.
FDA removed the suicidal-ideation warning
In January 2026 the FDA issued a safety communication based on its own meta-analysis of “91 placebo-controlled GLP-1 RA medication trials” with 107,910 patients and concluded there was no increased risk of suicidal ideation or behavior. It asked for the warning to be removed from the Wegovy, Saxenda and Zepbound labels [6]. The Wegovy label already shows the section as removed in 01/2026 [7].
Compounded products carry a separate signal
In FAERS (2018 to 2024), compared with non-compounded products, compounded GLP-1s had an ROR of 6.34 for suicidality. It is a disproportionality analysis and does not show cause [8]. The FDA’s reassurance comes from trials of approved products. It does not extend to preparations of unknown composition. The compounded GLP-1s article covers the other FAERS signals, and the compounded GLP-1 after the shortage guide covers when compounding is still allowed.
What this means for your practice
Screen alcohol use at intake and at follow-up, and record it. A reduction in drinking is a plausible effect, supported by three trials, and modest in size. Mood screening stays part of good care even with the warning gone. Prescribe approved products through a structured weight management program, and document the source when a patient arrives on a compounded one.
References
- Hendershot CS, et al. Once-weekly semaglutide in adults with alcohol use disorder: a randomized clinical trial. JAMA Psychiatry. 2025;82(4):395-405. PMID 39937469. Link
- Klausen MK, et al. Once-weekly semaglutide versus placebo in patients with alcohol use disorder and comorbid obesity. Lancet. 2026;407(10540):1687-1698. PMID 42070571. Link
- Schacht JP, et al. Oral semaglutide for alcohol use disorder: a randomized clinical trial. Am J Psychiatry. 2026;183(9):636-645. PMID 42522065. Link
- Lähteenvuo M, et al. Repurposing semaglutide and liraglutide for alcohol use disorder. JAMA Psychiatry. 2025;82(1):94-98. PMID 39535805. Link
- Wang W, et al. Associations of semaglutide with incidence and recurrence of alcohol use disorder in real-world population. Nat Commun. 2024;15(1):4548. PMID 38806481. Link
- U.S. Food and Drug Administration. Drug Safety Communication: FDA requests removal of suicidal behavior and ideation warning from glucagon-like peptide-1 receptor agonist (GLP-1 RA) medications. 13 January 2026. Link
- Novo Nordisk. Wegovy (semaglutide) US prescribing information, revised 06/2026. Link
- McCall KL, et al. Safety analysis of compounded GLP-1 receptor agonists: a pharmacovigilance study using the FDA adverse event reporting system. Expert Opin Drug Saf. 2026;25(3):581-588. PMID 40285721. Link
This is general information, not medical or legal advice. Rules vary by state and change. Confirm your own facts with counsel.